{
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "Hims & Hers Health (NYSE:HIMS) recently experienced a 5% price increase over the past quarter, marked by significant corporate events. The company was added to the S&P 400 index and simultaneously dropped from the S&P 600, highlighting a shift in its market positioning. Alongside this, its focus on strategic acquisitions, as indicated by the pursuit of lab diagnostic facilities, aligns with its growth strategy. Despite the market facing a 6% decline due to global trade tensions, Hims & Hers...",
                "publication_date": "2025-04-04T18:48:35.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4588",
                "source": "Simply Wall St.",
                "ticker": "HIMS",
                "title": "Hims & Hers Health (NYSE:HIMS) Rises 5% Over Last Quarter Following Strong 2024 Earnings",
                "url": "https://finance.yahoo.com/news/hims-hers-health-nyse-hims-184835498.html"
            },
            {
                "headline": "Hims & Hers Health (NYSE:HIMS) recently experienced a 5% price increase over the past quarter, marked by significant corporate events. The company was added to the S&P 400 index and simultaneously dropped from the S&P 600, highlighting a shift in its market positioning. Alongside this, its focus on strategic acquisitions, as indicated by the pursuit of lab diagnostic facilities, aligns with its growth strategy. Despite the market facing a 6% decline due to global trade tensions, Hims & Hers...",
                "publication_date": "2025-04-04T18:48:35.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4588",
                "source": "Simply Wall St.",
                "ticker": "HIMS",
                "title": "Hims & Hers Health (NYSE:HIMS) Rises 5% Over Last Quarter Following Strong 2024 Earnings",
                "url": "https://finance.yahoo.com/news/hims-hers-health-nyse-hims-184835498.html"
            }
        ],
        "avgScore": 0.4588
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of its core business growth. While the telehealth company has shown strong revenue expansion, questions remain about long-term profitability and customer retention. As a result, many analysts are adopting a cautious stance on HIMS stock, waiting for clearer signs of stability before making bullish calls. Let\u2019s look at key 2024 data on HIMS to understand why investors and ana",
                "publication_date": "2025-04-03T14:08:28.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7717",
                "source": "TipRanks",
                "ticker": "HIMS",
                "title": "Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty",
                "url": "https://finance.yahoo.com/news/analysts-stay-cautious-hims-stock-140828093.html"
            },
            {
                "headline": "Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of its core business growth. While the telehealth company has shown strong revenue expansion, questions remain about long-term profitability and customer retention. As a result, many analysts are adopting a cautious stance on HIMS stock, waiting for clearer signs of stability before making bullish calls. Let\u2019s look at key 2024 data on HIMS to understand why investors and ana",
                "publication_date": "2025-04-03T14:08:28.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7717",
                "source": "TipRanks",
                "ticker": "HIMS",
                "title": "Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty",
                "url": "https://finance.yahoo.com/news/analysts-stay-cautious-hims-stock-140828093.html"
            }
        ],
        "avgScore": 0.7717
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "It is hard to get excited after looking at Hims & Hers Health's (NYSE:HIMS) recent performance, when its stock has...",
                "publication_date": "2025-04-01T13:02:23.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.25",
                "source": "Simply Wall St.",
                "ticker": "HIMS",
                "title": "Hims & Hers Health, Inc.'s (NYSE:HIMS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?",
                "url": "https://finance.yahoo.com/news/hims-hers-health-inc-nyse-130223740.html"
            },
            {
                "headline": "Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day, including Johnson & Johnson's (JNJ) setback in its litigation. Additionally, Hims & Hers (HIMS) expanded its offerings, adding Eli Lilly's (LLY) GLP-1 drugs to its telehealth platform, following its earlier partnership with Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination&nbsp;here.",
                "publication_date": "2025-04-01T20:48:47.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "Yahoo Finance Video",
                "ticker": "HIMS",
                "title": "Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback",
                "url": "https://finance.yahoo.com/video/hims-hers-adds-eli-lilly-204847891.html"
            },
            {
                "headline": "Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day, including Johnson & Johnson's (JNJ) setback in its litigation. Additionally, Hims & Hers (HIMS) expanded its offerings, adding Eli Lilly's (LLY) GLP-1 drugs to its telehealth platform, following its earlier partnership with Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination&nbsp;here.",
                "publication_date": "2025-04-01T20:48:47.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "Yahoo Finance Video",
                "ticker": "HIMS",
                "title": "Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback",
                "url": "https://finance.yahoo.com/video/hims-hers-adds-eli-lilly-204847891.html"
            },
            {
                "headline": "It is hard to get excited after looking at Hims & Hers Health's (NYSE:HIMS) recent performance, when its stock has...",
                "publication_date": "2025-04-01T13:02:23.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.25",
                "source": "Simply Wall St.",
                "ticker": "HIMS",
                "title": "Hims & Hers Health, Inc.'s (NYSE:HIMS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?",
                "url": "https://finance.yahoo.com/news/hims-hers-health-inc-nyse-130223740.html"
            }
        ],
        "avgScore": 0.0992
    },
    "coef": -0.9967953321132533
}